–Presentation will include safety and efficacy data from 18 patients
with up to 12 months of follow-up–
–Company to host event with live webcast, Monday, June 5, 6:30 p.m.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 17, 2017--
bluebird bio, Inc. (Nasdaq:
BLUE), a clinical-stage company committed to developing potentially
transformative gene therapies for severe genetic diseases and T
cell-based immunotherapies for cancer, announced that updated interim
data from its study of bb2121, the company’s anti-BCMA CAR T cell
therapy will be presented at the American Society of Clinical Oncology
(ASCO) Annual Meeting in Chicago, Illinois. bb2121 is currently being
studied in a Phase 1 trial in patients with relapsed/refractory multiple
“This past November we presented the initial clinical data from the
first three dosing cohorts in this ongoing Phase 1 study of bb2121 in
patients with relapsed/refractory multiple myeloma. At ASCO in June, we
look forward to presenting data on those same patients with longer
follow-up, as well as safety and efficacy data on an additional 9
patients treated subsequently.” said David Davidson, M.D., chief medical
officer, bluebird bio. “These data will advance our understanding of the
bb2121 risk-benefit profile and inform planning with our partners at
Celgene for the dose expansion cohort of this study, and the design of a
potential pivotal study.”
First-in-Human Multicenter Study of bb2121 anti-BCMA CAR T Cell
Therapy for Relapsed/Refractory Multiple Myeloma: Updated Results
Presenter: Jesus G. Berdeja, M.D., Sarah Cannon Research
Institute and Tennessee Oncology, Nashville, TN
Monday, June 5, 2017, 4:45-6:00 pm CT (poster discussion); 8:00-11:30 am
Location: Hall D1
Session Title: Poster
Discussion Session: Developmental Therapeutics—Immunotherapy
The event and live webcast will begin at 6:30 p.m. CT (7:30 p.m. ET) on
Monday, June 5. To access the live webcast, please visit the “Events &
Presentations” page within the Investors and Media section of the
bluebird bio website at http://investor.bluebirdbio.com.
Replays of the webcast will be available on the bluebird bio website for
90 days following the event.
About bluebird bio, Inc.
With its lentiviral-based gene
therapies, T cell immunotherapy expertise and gene editing capabilities,
bluebird bio has built an integrated product platform with broad
potential application to severe genetic diseases and cancer. bluebird
bio’s gene therapy clinical programs include its Lenti-D™ product
candidate, currently in a Phase 2/3 study, called the Starbeam Study,
for the treatment of cerebral adrenoleukodystrophy, and its LentiGlobin™
product candidate, currently in four clinical studies for the treatment
of transfusion-dependent β-thalassemia, and severe sickle cell disease.
bluebird bio’s oncology pipeline is built upon the company’s leadership
in lentiviral gene delivery and T cell engineering, with a focus on
developing novel T cell-based immunotherapies, including chimeric
antigen receptor (CAR T) and T cell receptor (TCR) therapies. bluebird
bio’s lead oncology program, bb2121, is an anti-BCMA CAR T program
partnered with Celgene. bb2121 is currently being studied in a Phase 1
trial for the treatment of relapsed/refractory multiple myeloma.
bluebird bio also has discovery research programs utilizing
megaTAL/homing endonuclease gene editing technologies with the potential
for use across the company’s pipeline.
bluebird bio has operations in Cambridge, Massachusetts, Seattle,
Washington and Europe.
This release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements regarding
the Company’s bb2121 product candidate to treat relapsed/refractory
multiple myeloma. Any forward-looking statements are based on
management’s current expectations of future events and are subject to a
number of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied by
such forward-looking statements. These risks and uncertainties include,
but are not limited to, the risk that our bb2121 product candidate will
not be successfully developed, approved or commercialized. For a
discussion of other risks and uncertainties, and other important
factors, any of which could cause our actual results to differ from
those contained in the forward-looking statements, see the section
entitled “Risk Factors” in our most recent Form 10-Q, as well as
discussions of potential risks, uncertainties, and other important
factors in our subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date of
the release, and bluebird bio undertakes no duty to update this
information unless required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170517006149/en/
Source: bluebird bio, Inc.
bluebird bio, Inc.
Manisha Pai, 617-245-2107
Elizabeth Pingpank, 617-914-8736